review · Gut Microbes
Inflammatory bowel disease is a chronic gastrointestinal disorder characterised by recurring inflammation, where current standard therapies often demonstrate limited effectiveness and cause adverse side effects. This has motivated investigations into alternative treatment avenues. Bacterial membrane vesicles are nanoscale lipid particles released by Gram-negative and Gram-positive bacteria through lysis or blebbing. Carrying bioactive molecules and mirroring their parent bacteria, these vesicles play roles in initiating, progressing, and mitigating the disease. The research examines how bacterial membrane vesicles function in the development, diagnosis, and treatment of inflammatory bowel disease. It also reviews the technical obstacles currently limiting the field, outlines questions to guide future investigation, and assesses how understanding the interactions between these vesicles and inflammatory bowel disease can support the development of novel therapeutic approaches.
Current treatments for chronic gut inflammation often fail to work well or trigger unpleasant side effects. By exploring how tiny particles shed by bacteria influence both disease progression and healing, researchers can uncover fresh pathways for diagnosing and managing inflammatory bowel conditions, potentially improving options for patients living with these persistent disorders.
The findings point towards future applications in therapeutic delivery and diagnostic tools for inflammatory bowel disease, which could be relevant to biopharmaceutical developers and diagnostic device manufacturers. However, this review represents early-stage foundational research, noting significant technical challenges that must be resolved before clinical or commercial translation can occur.
AI-generated from the published abstract. Always read the original work before citing.
Inflammatory bowel disease (IBD) is a chronic and debilitating condition of relapsing and remitting inflammation in the gastrointestinal tract. Conventional therapeutic approaches for IBD have shown limited efficacy and detrimental side effects, leading to the quest for novel and effective treatment options for the disease. Bacterial membrane vesicles (MVs) are nanosized lipid particles secreted by lysis or blebbing processes from both Gram-negative and Gram-positive bacteria. These vesicles, known to carry bioactive components, are facsimiles of the parent bacterium and have been implicated in the onset and progression, as well as in the amelioration of IBD. This review discusses the overview of MVs and their impact in the pathogenesis, diagnosis, and treatment of IBD. We further discuss the technical challenges facing this research area and possible research questions addressing these challenges. We summarize recent advances in the diverse relationship between IBD and MVs, and the application of this knowledge as a viable and potent therapeutic strategy for IBD.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/19490976.2024.2341670
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
